Increased shear stress overcomes the antithrombotic platelet inhibitory effect of aspirin in stenosed dog coronary arteries.
暂无分享,去创建一个
[1] C. Patrono. Aspirin as an antiplatelet drug. , 1994, The New England journal of medicine.
[2] J. Moake,et al. Shear stress-induced von Willebrand factor binding to platelet glycoprotein Ib initiates calcium influx associated with aggregation. , 1992, Blood.
[3] V. Fuster,et al. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). , 1992, The New England journal of medicine.
[4] J. Folts. An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis. , 1991, Circulation.
[5] M. Noble,et al. Inhibition of acute platelet thrombosis formation in stenosed canine coronary arteries by specific serotonin 5HT2 receptor antagonist ritanserin. , 1990, Cardiovascular research.
[6] J. O'brien,et al. Shear-induced platelet aggregation , 1990, The Lancet.
[7] R. Jordan,et al. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor. Correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors. , 1989, Circulation.
[8] J. Eidt,et al. Specific Platelet Mediators and Unstable Coronary Artery Lesions: Experimental Evidence and Potential Clinical Implications , 1989, Circulation.
[9] D. Weber. Absolute diameter measurements of coronary arteries based on the first zero crossing of the Fourier spectrum. , 1989, Medical physics.
[10] J. O'brien,et al. Shear stress activation of platelet glycoprotein IIb/IIIa plus von Willebrand factor causes aggregation: filter blockage and the long bleeding time in von Willebrand's disease , 1987 .
[11] W. Campbell,et al. Cooperative mediation by serotonin S2 and thromboxane A2/prostaglandin H2 receptor activation of cyclic flow variations in dogs with severe coronary artery stenoses. , 1987, Circulation.
[12] B. Coller,et al. Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model. , 1986, Blood.
[13] H. Goldsmith,et al. Rheological Aspects of Thrombosis and Haemostasis: Basic Principles and Applications , 1986, Thrombosis and Haemostasis.
[14] C. Benedict,et al. Serotonin as a mediator of cyclic flow variations in stenosed canine coronary arteries. , 1986, Circulation.
[15] W. Campbell,et al. Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries. , 1984, Circulation.
[16] O. V. Miller,et al. Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis. , 1981, The Journal of pharmacology and experimental therapeutics.
[17] L. Hillis,et al. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. , 1981, The New England journal of medicine.
[18] J. Joist,et al. Role of platelet-prostaglandin synthesis in shear-induced platelet alterations. , 1980, Blood.
[19] M. Davies,et al. The relation of coronary thrombosis to ischaemic myocardial necrosis , 1979, The Journal of pathology.
[20] D. E. Gregg,et al. Regression and reappearance of coronary collaterals. , 1971, The American journal of physiology.
[21] M. Rosolowsky,et al. ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries. , 1992, Circulation research.
[22] J. Folts. A model of experimental arterial platelet thrombosis, platelet inhibitors, and their possible clinical relevance : an update , 1990 .
[23] E. Haber,et al. The heart and cardiovascular system , 1986 .
[24] D. Bergel. Cardiovascular fluid dynamics , 1972 .